# 医院获得性疾病检测市场 > 医院获得性感染检测市场研究报告，按检测方法（聚合酶链反应（PCR）、抗原检测、血清学检测、核酸检测）、按疾病类型（细菌感染、病毒感染、真菌感染、寄生虫感染）、按样本类型（血液样本、尿液样本、痰样本、拭子样本）、按最终用户（医院、诊断实验室、研究机构、居家护理环境）以及按地区（北美、欧洲、南美、亚太、中东和非洲） - 预测到2035年 - **Forecast Period:** 2025 - 2035 - **CAGR:** 6.69% - **2024:** $ 4.13 Billion - **2025:** $ 4.41 Billion - **2035:** $ 8.42 Billion - **Key Players:** Thermo Fisher Scientific (US), Roche Diagnostics (CH), Abbott Laboratories (US), Siemens Healthineers (DE), Becton Dickinson and Company (US), bioMerieux (FR), Hologic (US), Cepheid (US), Danaher Corporation (US) **Report ID:** MRFR/HC/30168-HCR · **Pages:** 128 · **Author:** Rahul Gotadki · **Last Updated:** May 15, 2026 **URL:** https://www.marketresearchfuture.com/reports/hospital-acquired-disease-testing-market-31954 --- ## Market Summary ## **Hospital-acquired Disease Testing Market Overview** As per MRFR analysis, the Hospital-acquired Disease Testing Market Size was estimated at 4.13 (USD Billion) in 2024. The Hospital-acquired Disease Testing Market Industry is expected to grow from 4.41 (USD Billion) in 2025 to 7.89 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 6.69% during the forecast period (2025 - 2034). ### **Key Hospital-acquired Disease Testing Market Trends Highlighted** The global hospital-acquired disease testing market is significantly influenced by various key market drivers. Increasing awareness about hospital-acquired infections and their implications has led to heightened demand for effective testing solutions among healthcare providers. This awareness is further amplified by stringent regulations and guidelines aimed at improving infection control protocols, which compel healthcare facilities to adopt comprehensive testing measures. The advancement of diagnostic technologies, including molecular diagnostics and rapid testing methods, has also bolstered the market, making it possible to identify pathogens quickly and accurately. Additionally, the rise in surgical procedures and the increasing number of immunocompromised patients are propelling the demand for robust testing options to mitigate the risk of infections. Opportunities to be explored within the market include the integration of artificial intelligence and machine learning into diagnostic processes. These advanced technologies can enhance the accuracy and efficiency of testing, offering quicker turnaround times for results and facilitating better clinical decision-making. Moreover, there is potential for collaboration between diagnostic companies and healthcare institutions to develop tailored testing solutions that address specific infection challenges. Recent times have witnessed a trend towards personalized medicine in the testing landscape, focusing on patient-specific factors that contribute to susceptibility to hospital-acquired infections. Moreover, the shift towards point-of-care testing is gaining traction, providing immediate results at the bedside and thereby improving patient outcomes. The ongoing emphasis on preventive healthcare and initiatives aimed at reducing infection rates further drive innovation in testing methodologies, indicating a promising future for the market. Overall, the intersection of technological advancements and growing healthcare concerns points toward a dynamic and evolving landscape in hospital-acquired disease testing. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **Hospital-acquired Disease Testing Market Drivers** Increasing Incidence of Hospital-acquired Infections The rising prevalence of hospital-acquired infections (HAIs) is a significant driver for the global hospital-acquired disease testing market. HAIs pose a serious health risk for patients undergoing treatment in healthcare facilities. These infections can lead to prolonged hospital stays, increased medical expenses, and a higher risk of mortality. The increasing incidence of HAIs has created a pressing need for effective testing solutions to diagnose and manage these infections promptly. Hospitals are increasingly recognizing the importance of reliable testing methods to ensure patient safety and prioritize infection control measures. This growing awareness is driving investments in advanced diagnostic technologies, thereby fostering market growth. Additionally, regulatory agencies and healthcare organizations are implementing stricter infection control guidelines and monitoring protocols, which further emphasizes the need for efficient testing solutions. Consequently, laboratories are focusing on developing innovative diagnostic tools and testing methods to address the escalating burden of HAIs. This focus on effective detection and monitoring is crucial in reducing infection rates and ensuring better health outcomes for patients, which, in turn, supports the expansion of the global hospital-acquired disease testing market. Technological Advancements in Diagnostic Solutions Technological advancements in diagnostic solutions are propelling the growth of the global hospital-acquired disease testing market. With the development of cutting-edge technologies such as molecular diagnostics, rapid testing, and automated laboratory equipment, healthcare providers can now conduct accurate and timely testing for hospital-acquired diseases. These innovative solutions not only enhance the sensitivity and specificity of test results but also minimize turnaround times, allowing for swift decision-making in patient care. The integration of artificial intelligence and machine learning algorithms to analyze test data is also paving the way for improved diagnostics. As technology continues to evolve, the healthcare sector is increasingly adopting these advanced testing methods to streamline operations and improve patient outcomes. Rising Awareness and Focus on Infection Control Rising awareness and focus on infection control among healthcare professionals and patients alike are vital drivers contributing to the growth of the global hospital-acquired disease testing market. As more information regarding HAIs and their impact on patient health circulates, stakeholders in the healthcare ecosystem are recognizing the importance of preventive measures and testing protocols. Educational initiatives aimed at informing healthcare workers about infection risks, as well as the implementation of stringent infection prevention strategies, are becoming commonplace in healthcare institutions. Furthermore, the increasing emphasis placed on patient safety, combined with the implementation of national and international guidelines for infection control, is driving demand for comprehensive testing services. Healthcare providers are investing in enhancing their testing capabilities to ensure adherence to these standards, which encourages market expansion. ## **Hospital-acquired Disease Testing Market Segment Insights** ### **Hospital-acquired Disease Testing Market Testing Methodology Insights** The segment's growth can be attributed to increasing awareness, advancements in diagnostic technologies, and the rising prevalence of hospital-acquired infections. Within Testing Methodology, the market is segmented into various techniques aimed at ensuring effective detection and management of these diseases. Among these, Polymerase Chain Reaction (PCR) testing helds significant value at 1.129 USD billion in 2023, emphasizing its efficacy in providing rapid and reliable results, thus dominating a crucial aspect of disease detection. [Carcinoembryonic Antigen](../../../reports/carcinoembryonic-antigen-market-772) demonstrates a notable market position with a value of 0.706 USD billion, highlighting its role in quickly identifying infections, especially in acute cases where timely diagnosis is critical. Meanwhile, Serological Testing reflected a value of 0.588 USD billion, playing an important role in assessing antibody responses and aiding in the understanding of the spread of infection. Nucleic Acid Testing, valued at 1.207 USD billion, stands out due to its high specificity and sensitivity, which is increasingly crucial as hospitals prioritize accuracy in diagnosing infection-causing pathogens. The overall landscape indicates a strategic focus on enhancing testing methodologies, aligning with the public health sector’s objective to reduce hospital-acquired infections effectively. As the global hospital-acquired disease testing market evolves, the importance of these testing methodologies becomes more pronounced. Market trends suggest an inclination towards incorporating advanced technologies, such as next-generation sequencing, within these methodologies to refine diagnostic accuracy and speed further. Growth drivers include escalating healthcare expenditures, heightened regulatory standards necessitating stringent testing protocols, and the rising burden of antibiotic-resistant infections. Challenges such as the high costs of advanced testing technologies and the need for skilled professionals for proper analysis continue to exist; however, opportunities for market expansion remain robust with ongoing research and development initiatives. Overall, the demand for effective testing methodologies that cater to the rapidly evolving landscape of hospital-acquired diseases is paramount to ensuring patient safety and healthcare quality. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ### **Hospital-acquired Disease Testing Market Type of Disease Insights** The global hospital-acquired disease testing market showcases a diverse landscape categorized by various types of diseases. Bacterial Infections represent a crucial focus due to their prevalence in hospital settings, often resulting in increased morbidity and healthcare costs. Similarly, Viral Infections are significant contributors to hospital-acquired diseases, with challenges posed by resistance and evolving viral strains. Fungal Infections have gained attention, particularly with the rise of immuno-compromised patients, amplifying the need for effective testing solutions. Parasitic Infections also pose threats; although they are less common, they can lead to severe complications in hospitalized patients. The varied landscape within the global hospital-acquired disease testing market segmentation highlights the importance of tailored diagnostic approaches to improve patient outcomes and optimize treatment protocols. This market reflects ongoing trends toward enhancing testing capabilities amid rising healthcare demands, with opportunities arising from technological advancements and increased awareness about infection control. ### **Hospital-acquired Disease Testing Market Sample Type Insights** The segment includes various sample types such as Blood Samples, Urine Samples, Sputum Samples, and Swab Samples. Each sample type plays a crucial role in diagnosing hospital-acquired infections, with blood samples often being at the forefront due to their ability to detect severe systemic infections rapidly. Urine samples are also critical as they help identify urinary tract infections, which are common in hospitalized patients. Sputum samples serve to diagnose respiratory infections, which pose considerable risks in healthcare settings. Swab samples, typically used for skin and mucosal investigations, are significant for detecting pathogens in localized areas. The inclusion of diverse sample types within the global hospital-acquired disease testing market segmentation facilitates comprehensive testing strategies, enhancing patient diagnosis and care. As the market continues its upward trajectory, the demand for various sample types remains pivotal in improving healthcare outcomes and addressing the challenges posed by hospital-acquired diseases, providing ample opportunities for further innovation and market growth. ### **Hospital-acquired Disease Testing Market End User Insights** The segment is primarily composed of hospitals, diagnostic laboratories, research institutions, and home care settings, each playing a vital role in addressing hospital-acquired diseases. Hospitals are a major contributor, as they account for a majority of testing, driven by the need to ensure patient safety and control infection outbreaks. Diagnostic laboratories also hold a significant share, providing essential testing services that aid in rapid diagnosis and treatment decisions. Research institutions further support the market by developing innovative testing methodologies and vaccines, enhancing the overall understanding of hospital-acquired infections. Additionally, the relevance of home care settings has grown, as they offer convenient testing options that align with the increasing trend toward patient-centered care. The global hospital-acquired disease testing market data showcases how each End User contributes to the market growth in response to the rising awareness and regulatory emphasis on infection prevention. Various challenges, including rising healthcare costs and resource limitations, are balanced by opportunities arising from technological advancements and increased healthcare expenditure. The market statistics reflect a dynamic landscape as it adapts to meet the complex needs of each segment. ### **Hospital-acquired Disease Testing Market Regional Insights** The global hospital-acquired disease testing market revenue reflects a diverse landscape across various regions, showing substantial promise for growth. In 2023, the North American segment led with a valuation of 1.45 USD billion, making it a major contributor, driven by advanced healthcare infrastructure and high awareness of disease prevention. Europe followed closely with a valuation of 1.05 USD billion, highlighting the region's commitment to improving patient safety and healthcare quality. Asia Pacific, valued at 0.85 USD billion, was significant due to rapid healthcare advancements and increasing patient populations, while the Middle East and Africa stood at 0.13 USD billion, showcasing the potential for future development as healthcare facilities expand. Meanwhile, South America, valued at 0.15 USD billion, reflected ongoing growth as healthcare initiatives gained traction. Each region's unique challenges and opportunities shape the dynamics of the global hospital-acquired disease testing market, influencing market growth trends and the overall segmentation in a contributing manner. The continuous need for better healthcare outcomes drives investments in testing technologies across these diverse regions, making the market increasingly competitive and critical for disease management in hospitals. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **Hospital-acquired Disease Testing Market Key Players and Competitive Insights** The global hospital-acquired disease testing market is characterized by a complex landscape of well-established players and emerging companies striving for competitive advantage. As the incidence of nosocomial infections rises due to various factors such as antibiotic resistance and patient vulnerability, there is an increasing demand for testing solutions that are efficient and accurate. The market dynamics are influenced by extensive research and development efforts as manufacturers invest in innovating diagnostic technologies, including molecular diagnostics, immunoassays, and rapid testing solutions. Competitive insights reveal a focus on technological advancements, partnerships, and acquisitions as key strategies for companies aiming to enhance their product offerings and strengthen their market position. Additionally, regulatory compliance and sustainable practices are becoming increasingly important as stakeholders seek reliable and responsible testing mechanisms in the healthcare sector. Thermo Fisher Scientific has established itself as a major player in the global hospital-acquired disease testing market through its commitment to innovation and quality. The company's extensive portfolio includes a range of diagnostic tests specifically designed to detect pathogens that cause hospital-acquired infections. This focus on developing high-performance products underlines its strength in delivering reliable results rapidly, which is crucial in clinical settings where timely intervention can significantly impact patient outcomes. Moreover, Thermo Fisher Scientific's strong market presence is supported by its robust distribution networks and collaborations with healthcare providers, ensuring that its testing solutions reach a wide audience. The company also benefits from ongoing investments in research and development, allowing it to stay ahead of competitors by introducing cutting-edge technologies that meet the evolving industry’s needs. PerkinElmer is another key player in the global hospital-acquired disease testing market known for its advanced diagnostic solutions and emphasis on leveraging technology to improve patient care. The company offers a range of products focused on the detection and monitoring of infections that can be acquired in hospital settings, reinforcing its reputation for reliability and precision. PerkinElmer strengthens its market position with innovative testing platforms that utilize automation and multiplexing capabilities, enhancing throughput and allowing healthcare facilities to manage multiple tests simultaneously. The company's strategic initiatives, including partnerships and collaborations within the healthcare community, contribute to the effective distribution of its products, ensuring that hospitals and clinical labs have access to effective testing solutions. With its continuous investment in developing accurate and efficient testing technologies, PerkinElmer remains a formidable competitor in the market, committed to addressing the challenges posed by hospital-acquired diseases. **Key Companies in the hospital-acquired disease testing market Include** ### Hospital acquired Disease Testing Market Industry Developments - **Q2 2024: bioMérieux Launches VIDAS® B·R·A·H·M·S PCT™ Test for Early Detection of Sepsis** bioMérieux announced the launch of its VIDAS® B·R·A·H·M·S PCT™ test, designed for the early detection of sepsis and hospital-acquired infections, expanding its diagnostic portfolio for critical care settings. - **Q2 2024: QuidelOrtho Receives FDA Clearance for Sofia 2 SARS Antigen FIA for Hospital Use** QuidelOrtho received FDA clearance for its Sofia 2 SARS Antigen FIA, enabling rapid detection of SARS-CoV-2 in hospital settings and supporting infection control efforts for hospital-acquired diseases. - **Q2 2024: OpGen Announces Partnership with BioVersys to Develop Rapid Diagnostic Tests for Hospital-Acquired Infections** OpGen entered a partnership with BioVersys to co-develop rapid diagnostic tests targeting multidrug-resistant hospital-acquired infections, aiming to improve patient outcomes and infection control. - **Q1 2024: Thermo Fisher Scientific Acquires Olink Holding AB to Expand Infectious Disease Testing Portfolio** Thermo Fisher Scientific completed the acquisition of Olink Holding AB, strengthening its capabilities in hospital-acquired disease testing and expanding its infectious disease diagnostics portfolio. - **Q2 2024: Cepheid Launches Xpert® HAI Panel for Rapid Detection of Hospital-Acquired Infections** Cepheid launched the Xpert® HAI Panel, a molecular diagnostic test designed for the rapid detection of common hospital-acquired infections, enabling faster clinical decision-making in healthcare facilities. - **Q1 2024: Roche Receives CE Mark for cobas® HAI Test for European Hospitals** Roche received CE Mark approval for its cobas® HAI test, allowing European hospitals to implement rapid screening for hospital-acquired infections and improve infection control protocols. - **Q2 2024: Accelerate Diagnostics Announces $25 Million Series C Funding to Advance Hospital-Acquired Infection Testing** Accelerate Diagnostics raised $25 million in Series C funding to support the development and commercialization of new rapid tests for hospital-acquired infections. - **Q1 2024: BD Launches BD MAX™ HAI Assay for Detection of Multidrug-Resistant Organisms** BD (Becton, Dickinson and Company) launched the BD MAX™ HAI Assay, a molecular test for the detection of multidrug-resistant organisms associated with hospital-acquired infections. - **Q2 2024: Siemens Healthineers Opens New Diagnostic Manufacturing Facility Focused on Hospital-Acquired Infection Testing** Siemens Healthineers opened a new manufacturing facility dedicated to producing diagnostic tests for hospital-acquired infections, aiming to meet growing demand in healthcare settings. - **Q1 2024: Abbott Receives FDA Approval for Alinity m HAI Test for Hospital Use** Abbott received FDA approval for its Alinity m HAI test, enabling hospitals to rapidly detect and manage hospital-acquired infections with improved accuracy. - **Q2 2024: Merck Announces Strategic Partnership with GenMark Diagnostics for Hospital-Acquired Infection Testing Solutions** Merck entered a strategic partnership with GenMark Diagnostics to co-develop and commercialize advanced testing solutions for hospital-acquired infections. - **Q1 2024: Mobidiag Secures €15 Million Funding to Expand Hospital-Acquired Infection Diagnostic Portfolio** Mobidiag secured €15 million in funding to accelerate the development and market introduction of new diagnostic tests for hospital-acquired infections. ## **Hospital-acquired Disease Testing Market Segmentation Insights** ### **Hospital-acquired Disease Testing Market Testing Methodology Outlook** ### **Hospital-acquired Disease Testing Market Type of Disease Outlook** ### **Hospital-acquired Disease Testing Market Sample Type Outlook** ### **Hospital-acquired Disease Testing Market End User Outlook** ### **Hospital-acquired Disease Testing Market Regional Outlook** ## Market Drivers ### 监管合规与质量标准 医院获得性感染检测市场的监管合规性和质量标准遵循是影响其发展的关键因素。医疗机构越来越需要遵循卫生当局制定的严格法规，以确保患者安全和护理质量。遵守这些法规通常需要采用先进的检测方法，以准确诊断和监测医院获得性感染。维持高标准护理的压力促使医院投资于符合监管要求的可靠检测解决方案。因此，预计这一趋势将推动医院获得性感染检测市场的增长，因为医疗服务提供者寻求增强其合规努力。 ### 诊断工具中的技术创新 诊断工具的技术进步正在显著影响医院获得性疾病检测市场。快速分子检测、即时检测和自动化实验室系统等创新正在提高疾病检测的速度和准确性。例如，下一代测序技术的引入允许全面的病原体识别，这在有效管理医院获得性感染（HAIs）中至关重要。预计诊断检测市场将增长，估计在未来几年复合年增长率超过10%。这些进步不仅改善了患者的治疗结果，还简化了医院的运营，使其成为医院获得性疾病检测市场的重要组成部分。 ### 日益增强的患者安全意识 随着医疗服务提供者和患者对患者安全意识的提高，医院获得性疾病检测市场正在蓬勃发展。旨在突出医院获得性感染（HAI）相关风险的教育倡议和活动，导致对感染预防策略的关注加剧。医院现在优先实施严格的检测协议，以确保患者安全并改善整体护理质量。这种思维方式的转变反映在对能够快速识别感染病原体的检测解决方案的日益采用上。因此，随着利益相关者认识到主动疾病管理的重要性，医院获得性疾病检测市场可能会经历持续增长。 ### 医院获得性感染发生率上升 医院获得性感染（HAIs）的日益普遍是医院获得性疾病检测市场的主要驱动因素。报告显示，HAIs每年影响数百万患者，导致住院时间延长和医疗费用增加。美国疾病控制与预防中心估计，在任何一天，31名住院患者中就有1人至少感染1种HAI。这个令人震惊的统计数据突显了迫切需要有效的检测解决方案，以及时识别和管理这些感染。随着医疗机构努力提高患者安全性和降低感染率，对先进检测方法的需求可能会激增，从而推动医院获得性疾病检测市场的发展。 ### 增加对医疗基础设施的投资 医疗基础设施投资的激增是医院获得性疾病检测市场的一个显著驱动因素。各国政府和私营实体正在分配大量资源以提升医院设施，包括升级诊断能力。这种投资在发展中地区尤为明显，在这些地区，新医疗设施的建立伴随着先进检测技术的实施。随着医院扩展服务并改善感染控制措施，对有效疾病检测解决方案的需求预计将上升。这一趋势表明医院获得性疾病检测市场将呈现强劲的增长轨迹，因为医疗服务提供者寻求降低与医院获得性感染（HAIs）相关的风险。 ## Future Outlook 医院获得性感染检测市场预计将在2024年至2035年间以6.69%的年均增长率增长，推动因素包括技术进步、意识提高和监管支持。 **New opportunities:** - 开发快速诊断试剂盒以进行现场检测 整合基于人工智能的分析以进行预测性测试 扩展远程医疗服务以进行远程疾病监测 到2035年，市场预计将会强劲，受到创新和战略合作伙伴关系的推动。 ## Segment Insights ### 通过测试方法：PCR（最大）与抗原测试（增长最快） 医院获得性感染检测市场在检测方法上变得越来越多样化。其中，聚合酶链反应（PCR）检测作为最大的细分市场，因其在检测广泛病原体方面的准确性和可靠性而占据了显著的市场份额。抗原检测虽然在比例上不如PCR检测大，但由于其提供更快的结果，正在获得动力，吸引希望提高诊断效率的医疗机构。近年来，快速检测方法的明显转变使得抗原检测成为该细分市场中增长最快的方法。对医院获得性感染的及时诊断和治疗的需求是这一变化的关键驱动因素，医疗提供者认识到需要立即获得结果以减少感染传播并改善患者结果。这一趋势反映了诊断技术的更广泛进步，使得传统方法之外的更快和更灵活的检测选项成为可能。 PCR（主导）与血清学检测（新兴） 聚合酶链反应（PCR）检测仍然是医院获得性疾病检测市场的主导力量，以其在识别感染性病原体，特别是病毒和细菌病原体方面的特异性和灵敏度而闻名。其建立的可靠性使其成为临床环境中的首选方法，确保准确的诊断。相反，血清学检测代表了一种新兴趋势，专注于检测血液中的抗体。由于其揭示过去感染和评估免疫反应的潜力，这种方法正在获得关注。尽管通常比PCR慢，但技术进步和改进的测试设计正在增强其吸引力，使其成为理解医疗环境中感染动态的补充方法。 ### 按疾病类型：细菌感染（最大）与病毒感染（增长最快） 在医院获得性感染检测市场中，细菌感染占据了最大的份额，因为它们在医院环境中普遍存在。常见的病原体如耐甲氧西林金黄色葡萄球菌（MRSA）和艰难梭菌是医疗相关感染的重要贡献者。该细分市场的主导地位主要得益于不断的监测和检测，这些都是由不断变化的指南和公共卫生倡议推动的。尽管病毒感染目前是增长最快的细分市场，但由于对流感、诺如病毒以及新兴病原体如COVID-19的认识增加，它们正在获得关注。这一增长得益于快速检测技术的进步以及对感染控制协议的增强关注，这些协议优先考虑在医疗环境中检测病毒威胁。 细菌感染：主导与病毒感染：新兴 细菌感染在医院获得性疾病检测市场中占据主导地位，主要由于其高发病率以及对患者发病率和死亡率的重大影响。对有效检测方法的需求促使细菌检测技术的创新，从而实现了更高效的诊断过程。相反，尽管病毒感染正在出现，但迅速意识到增强检测能力的必要性。尤其是在全球健康危机期间，病毒检测需求的激增表明了向主动感染控制措施的转变。随着医疗机构优先考虑病毒威胁的早期检测，预计针对病毒病原体的诊断工具和方法的投资将增加，进一步塑造竞争格局。 ### 按样本类型：血液样本（最大）与拭子样本（增长最快） 在医院获得性疾病检测市场中，血液样本占据了市场份额，代表了用于诊断测试的最广泛使用的样本类型。它们的突出地位被广泛归因于医院中已建立的检测协议以及血液相关测试对感染的重要性。相反，拭子样本正在迅速获得关注，因为越来越多的医疗机构采用利用拭子的检测方法，这一趋势是由于对更少侵入性程序的需求，从而在市场中占据了显著份额。 血液样本（主导）与拭子样本（新兴） 血液样本长期以来被视为医院疾病检测的支柱，因为它们能够提供患者健康状况的全面洞察。它们在市场上的主导地位得益于广泛的检测协议和多种可用测试。相比之下，拭子样本作为一种更少侵入性的替代方案正在崛起，增长受到检测技术进步和对快速结果日益增长的需求的推动。医院越来越认识到拭子检测在筛查和诊断多种医院获得性感染方面的好处，从而扩大了其在临床环境中的使用。 ### 按最终用户：医院（最大）与诊断实验室（增长最快） 在医院获得性疾病检测市场中，医院代表了最大的细分市场，利用其在住院护理中的关键作用，确保及时诊断和管理医院获得性感染。诊断实验室紧随其后，占据了重要份额，同时在通过全面的检测服务支持医院和各种医疗环境方面发挥着重要作用。研究机构和居家护理环境是较小的细分市场，但仍然至关重要，研究机构在检测方法的进步中提供帮助，而居家护理环境则专注于患者便利性和分散检测选项。 医院：主导与居家护理环境：新兴 医院在医院获得性疾病检测市场中仍然是主导力量，因为它们的患者数量庞大，并且迫切需要有效的感染控制措施。它们已经建立了快速检测的协议，以防止疫情爆发，并得到了熟练的医疗专业人员的支持。另一方面，家庭护理环境正在成为一个重要趋势，满足需要在更舒适环境中进行检测的患者。这一转变是由即时护理技术的进步和患者对居家护理的偏好增加所推动的，导致对门诊服务和远程监测的关注度提高。 ## Regional Market Share Analysis 全球医院获得性疾病检测市场的收入反映了各个地区的多样化格局，显示出可观的增长潜力。在2023年，北美地区以14.5亿美元的估值领先，成为主要贡献者，得益于先进的医疗基础设施和对疾病预防的高度意识。 欧洲紧随其后，估值为10.5亿美元，突显了该地区对改善患者安全和医疗质量的承诺。 亚太地区的估值为8.5亿美元，由于医疗技术的快速进步和患者数量的增加而显得重要，而中东和非洲的估值为1.3亿美元，展示了随着医疗设施的扩展，未来发展的潜力。 与此同时，南美的估值为1.5亿美元，反映了随着医疗倡议的推进而持续增长的态势。 每个地区独特的挑战和机遇塑造了全球医院获得性疾病检测市场的动态，影响市场增长趋势和整体细分。 对更好医疗结果的持续需求推动了对这些多样化地区检测技术的投资，使市场竞争日益激烈，并对医院的疾病管理至关重要。 来源：初步研究，二次研究，_市场研究未来_数据库和分析师评审 ## Competitive Benchmarking 全球医院获得性感染检测市场的特点是由众多成熟企业和新兴公司组成的复杂格局，这些公司努力寻求竞争优势。由于抗生素耐药性和患者脆弱性等多种因素，医院感染的发生率不断上升，对高效、准确的检测解决方案的需求也在增加。 市场动态受到广泛的研究和开发工作的影响，制造商在创新诊断技术方面进行投资，包括分子诊断、免疫测定和快速检测解决方案。 竞争洞察显示，技术进步、合作伙伴关系和收购是公司增强产品供应和巩固市场地位的关键策略。此外，监管合规和可持续实践变得越来越重要，因为利益相关者寻求在医疗保健领域可靠和负责任的检测机制。 赛默飞世尔科技凭借其对创新和质量的承诺，已在全球医院获得性感染检测市场中确立了重要地位。该公司的广泛产品组合包括一系列专门设计用于检测导致医院获得性感染的病原体的诊断测试。 这种对开发高性能产品的关注突显了其在快速提供可靠结果方面的优势，这在临床环境中至关重要，因为及时干预可以显著影响患者的结果。 此外，赛默飞世尔科技强大的市场存在得益于其稳健的分销网络和与医疗服务提供者的合作，确保其检测解决方案能够覆盖广泛的受众。 该公司还受益于持续的研发投资，使其能够通过引入满足不断变化的行业需求的尖端技术，保持领先于竞争对手。 珀金埃尔默是全球医院获得性感染检测市场的另一重要参与者，以其先进的诊断解决方案和利用技术改善患者护理的重视而闻名。该公司提供一系列专注于检测和监测医院环境中可能获得的感染的产品，强化了其在可靠性和精确性方面的声誉。 珀金埃尔默通过利用自动化和多重检测能力的创新检测平台增强其市场地位，提高了通量，使医疗机构能够同时管理多项检测。 该公司的战略举措，包括与医疗社区的合作伙伴关系和合作，有助于其产品的有效分销，确保医院和临床实验室能够获得有效的检测解决方案。 凭借对开发准确和高效检测技术的持续投资，珀金埃尔默在市场上仍然是一个强大的竞争者，致力于应对医院获得性感染带来的挑战。 ## Recent News & Developments - **2024年第二季度：bioMérieux推出VIDAS® B·R·A·H·M·S PCT™测试以早期检测脓毒症** bioMérieux宣布推出其VIDAS® B·R·A·H·M·S PCT™测试，旨在早期检测脓毒症和医院获得性感染，扩展其在重症监护环境中的诊断产品组合。 - **2024年第二季度：QuidelOrtho获得FDA批准用于医院的Sofia 2 SARS抗原FIA** QuidelOrtho获得FDA批准其Sofia 2 SARS抗原FIA，能够在医院环境中快速检测SARS-CoV-2，并支持医院获得性疾病的感染控制工作。 - **2024年第二季度：OpGen宣布与BioVersys合作开发医院获得性感染的快速诊断测试** OpGen与BioVersys达成合作，共同开发针对多重耐药医院获得性感染的快速诊断测试，旨在改善患者结果和感染控制。 - **2024年第一季度：Thermo Fisher Scientific收购Olink Holding AB以扩展传染病检测产品组合** Thermo Fisher Scientific完成对Olink Holding AB的收购，增强其在医院获得性疾病检测方面的能力，并扩展其传染病诊断产品组合。 - **2024年第二季度：Cepheid推出Xpert® HAI面板以快速检测医院获得性感染** Cepheid推出Xpert® HAI面板，这是一种分子诊断测试，旨在快速检测常见的医院获得性感染，从而在医疗机构中实现更快的临床决策。 - **2024年第一季度：罗氏获得欧盟医院用cobas® HAI测试的CE标志** 罗氏获得其cobas® HAI测试的CE标志批准，使欧洲医院能够实施医院获得性感染的快速筛查，并改善感染控制协议。 - **2024年第二季度：Accelerate Diagnostics宣布获得2500万美元C轮融资以推进医院获得性感染检测** Accelerate Diagnostics获得2500万美元的C轮融资，以支持新型医院获得性感染快速测试的开发和商业化。 - **2024年第一季度：BD推出BD MAX™ HAI检测以检测多重耐药生物体** BD（贝克顿、迪金森公司）推出BD MAX™ HAI检测，这是一种用于检测与医院获得性感染相关的多重耐药生物体的分子测试。 - **2024年第二季度：西门子医疗开设新的诊断制造设施，专注于医院获得性感染检测** 西门子医疗开设了一家新的制造设施，专门生产医院获得性感染的诊断测试，旨在满足医疗环境中日益增长的需求。 - **2024年第一季度：雅培获得FDA批准用于医院的Alinity m HAI测试** 雅培获得FDA批准其Alinity m HAI测试，使医院能够快速检测和管理医院获得性感染，并提高准确性。 - **2024年第二季度：默克宣布与GenMark Diagnostics建立战略合作伙伴关系以开发医院获得性感染检测解决方案** 默克与GenMark Diagnostics建立战略合作伙伴关系，共同开发和商业化医院获得性感染的先进检测解决方案。 - **2024年第一季度：Mobidiag获得1500万欧元融资以扩展医院获得性感染诊断产品组合** Mobidiag获得1500万欧元的融资，以加速新型医院获得性感染诊断测试的开发和市场推出。 ## Report Scope | 2024年市场规模 | 4.129（十亿美元） | | --- | --- | | 2025年市场规模 | 4.406（十亿美元） | | 2035年市场规模 | 8.42（十亿美元） | | 年复合增长率（CAGR） | 6.69%（2024 - 2035） | | 报告覆盖范围 | 收入预测、竞争格局、增长因素和趋势 | | 基准年 | 2024 | | 市场预测期 | 2025 - 2035 | | 历史数据 | 2019 - 2024 | | 市场预测单位 | 十亿美元 | | 主要公司简介 | 市场分析进行中 | | 覆盖的细分市场 | 市场细分分析进行中 | | 主要市场机会 | 先进诊断技术的整合增强了医院获得性疾病检测市场的早期检测。 | | 主要市场动态 | 日益严格的监管审查和技术进步推动医院获得性疾病检测解决方案的创新。 | | 覆盖的国家 | 北美、欧洲、亚太、南美、中东和非洲 | ## Frequently Asked Questions **Q: 到2035年，医院获得性疾病检测市场的预计市场估值是多少？** A: 预计到2035年，医院获得性疾病检测市场的市场估值将达到84.2亿美元。 **Q: 2024年医院获得性疾病检测市场的市场估值是多少？** A: 2024年医院获得性疾病检测市场的整体市场估值为41.29亿美元。 **Q: 在2025年至2035年的预测期内，医院获得性疾病检测市场的预期CAGR是多少？** A: 在2025年至2035年的预测期内，医院获得性疾病检测市场的预期CAGR为6.69%。 **Q: 在医院获得性疾病检测市场中，哪些测试方法处于领先地位？** A: 主要的检测方法包括聚合酶链反应（PCR）、抗原检测和血清学检测，其中PCR预计将从15亿美元增长到30亿美元。 **Q: 医院获得性感染检测市场主要测试哪些类型的疾病？** A: 主要检测的疾病类型包括细菌感染、病毒感染、真菌感染和寄生虫感染，其中细菌感染预计将从15亿到31亿美元增长。 **Q: 医院获得性疾病检测市场使用了哪些样本类型？** A: 所使用的样本类型包括血液样本、尿液样本、痰样本和拭子样本，其中血液样本预计将从15亿到31亿美元增长。 **Q: 医院获得性感染检测市场的关键参与者是谁？** A: 市场上的主要参与者包括赛默飞世尔科技、罗氏诊断、雅培实验室和西门子医疗。 **Q: 医院获得性感染检测市场的最终用户细分是什么？** A: 最终用户细分包括医院、诊断实验室、研究机构和居家护理环境，预计医院的市场规模将从15亿到32亿美元增长。 **Q: 病毒感染的市场估值与细菌感染相比如何？** A: 病毒感染市场预计将从12亿美元增长到25亿美元，这一增长低于细菌感染市场从15亿美元增长到31亿美元。 **Q: 医院获得性疾病检测市场对医疗服务提供者的意义是什么？** A: 医院获得性感染检测市场对医疗服务提供者至关重要，因为它增强了疾病的检测和管理，从而改善了患者的结果。 --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/hospital-acquired-disease-testing-market-31954*